Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.

Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF

Open source

DOI: 10.1182/bloodadvances.2023011741
Published: 2024 Apr 23
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2023011741,
  title = {Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.},
  author = {Stilgenbauer S and Tausch E and Roberts AW and Davids MS and Eichhorst B and Hallek M and Hillmen P and Schneider C and Schetelig J and Böttcher S and Kater AP and Jiang Y and Boyer M and Popovic R and Ghanim MT and Moran M and Sinai WJ and Wang X and Mukherjee N and Chyla B and Wierda WG and Seymour JF},
  year = {2024},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2023011741},
  url = {https://doi.org/10.1182/bloodadvances.2023011741}
}

RIS

TY  - JOUR
TI  - Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
AU  - Stilgenbauer S
AU  - Tausch E
AU  - Roberts AW
AU  - Davids MS
AU  - Eichhorst B
AU  - Hallek M
AU  - Hillmen P
AU  - Schneider C
AU  - Schetelig J
AU  - Böttcher S
AU  - Kater AP
AU  - Jiang Y
AU  - Boyer M
AU  - Popovic R
AU  - Ghanim MT
AU  - Moran M
AU  - Sinai WJ
AU  - Wang X
AU  - Mukherjee N
AU  - Chyla B
AU  - Wierda WG
AU  - Seymour JF
PY  - 2024
JO  - Blood advances
DO  - 10.1182/bloodadvances.2023011741
UR  - https://doi.org/10.1182/bloodadvances.2023011741
ER  -

APA

S, S., E, T., AW, R., MS, D., B, E., M, H., P, H., C, S., J, S., S, B., AP, K., Y, J., M, B., R, P., MT, G., M, M., WJ, S., X, W., N, M., B, C., WG, W., & JF, S. (2024). Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.. Blood advances. https://doi.org/10.1182/bloodadvances.2023011741

Source records

pubmed · retrieved 2026-09-27T08:37:57.196Z